#Hong Kong #Akeso #Ivonescimab #NSCLC

Promising Phase II Study Results of Ivonescimab for NSCLC

In a significant breakthrough in the treatment of resectable non-small cell lung cancer (NSCLC), Akeso, Inc. has announced the publication of encouraging results from a Phase II clinical trial of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab. This research, appearing in Nature Medicine, highlights the treatment's efficacy and safety within a perioperative setting, raising hopes for patients facing this challenging disease.

Study Overview

The Phase II trial investigated ivonescimab administered as either a standalone treatment or in conjunction with chemotherapy as part of a perioperative regimen. The treatment commenced with neoadjuvant therapy, followed by surgical intervention, and concluded with adjuvant ivonescimab. The trial aimed to ascertain its potential in improving pathological responses in patients undergoing surgery for resectable NSCLC.

Key Findings

The results were compelling. In the cohort receiving ivonescimab alongside chemotherapy, the major pathological response (MPR) rate reached 70.1%, with a pathological complete response (pCR) rate of 50.7%. Among other promising results, 68.7% of these patients showed residual viable tumor (RVT) at or below 5%. Even those receiving ivonescimab monotherapy exhibited notable responses, achieving an MPR of 60% and a pCR of 30%.

These findings indicate not only the potential efficacy of ivonescimab but also the importance of the treatment in reducing tumor burden before surgical intervention. All patients in the trial who underwent surgery achieved R0 resection (a complete tumor removal), highlighting the effectiveness of this treatment avenue. The event-free survival (EFS) rate over 12 months post-treatment was an impressive over 80% for both groups, suggesting that ivonescimab could significantly improve long-term outcomes for patients.

Subgroup Analyses

Further subgroup evaluations unveiled even more promising insights, particularly among subpopulations often considered harder to treat. For instance, patients with squamous histology received an MPR rate of 81.5%, and those categorized with Stage III disease observed a 65.5% MPR. Interestingly, the MPR for PD-L1-negative patients was shown to be competitive with those expressing PD-L1, suggesting broader applicability of ivonescimab across diverse patient profiles.

Safety Profile

The safety aspect of the trial also garnered attention, as the treatment's perioperative profile was characterized as manageable with no occurrences of grade ≥3 bleeding events, underscoring the potential of ivonescimab as a safer alternative compared to current treatment regimens. Notably, no surgical procedures were cancelled due to treatment-related adverse effects, signifying the robustness of this therapy.

Treatment Landscape and Future Implications

Current treatment protocols for resectable NSCLC often leave patients vulnerable to the recurrence of disease, with rates of 30–70% post-surgery. Consequently, the published outcomes from this Phase II study illuminate a vital gap in existing treatment options, particularly benefiting patients with critical characteristics such as Stage IIIB disease, squamous histology, and negative PD-L1 status.

These findings not only bolster the case for ivonescimab as a pivotal next-generation immunotherapy but also align with Akeso’s aggressive development strategy aimed at establishing ivonescimab as a mainstay in treatment regimens.

About Ivonescimab

Ivonescimab is not only a groundbreaking bispecific antibody but represents a novel approach by combining immunotherapy with anti-angiogenesis. It is touted as the first of its kind to deliver promising results compared to pembrolizumab in Phase III trials. Akeso has ambitious plans for ivonescimab, with over 17 ongoing Phase III studies across various cancer types, promising greater accessibility to this innovative treatment in the future.

Conclusion

As Akeso continues to expand its reach within the biopharmaceutical space, the promising data surrounding ivonescimab offers new hope for patients battling NSCLC. With its proven efficacy and manageable safety profile, this bispecific antibody paves the way for potentially reshaping standards of care in oncology worldwide.